Novo Nordisk's Wegovy, a weight loss drug, will soon be accessible to US customers via telehealth platforms like Hims & Hers, LifeMD, and Ro, offering a reduced monthly price of $449. Novo Nordisk ...

Q1 Wegovy sales rose 85% to DKK 17.36 billion; Ozempic up 18% to DKK 32.72 billion. Novo Nordisk's Q1 sales hit $10.89 billion, missing the $11.64 billion consensus estimate. Unlock your all-in ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Toni's uncle, Ronald Gaffney, was killed in Vietnam in 1965. Boxes for the medications Wegovy and Zepbound are arranged for a photograph in California on Thursday, May 8, 2025. (AP Photo/JoNel ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings. kAm!6@A=6 E2<:?8 t=: {:==J’D @36D:EJ 5CF8[ k2 ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications.

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients. By Rebecca Robbins ...

The first head-to-head trial of two blockbuster weight-loss drugs has shown Mounjaro is more effective than rival Wegovy. Both drugs led to substantial weight loss, but Mounjaro's 20% weight ...

If the U.S. Food and Drug Administration agrees to allow Novo Nordisk to expand the prescription’s label, Wegovy would become the first oral GLP-1 treatment for obesity management.

Boxes for the medications Wegovy and Zepbound are arranged for a photograph in California on Thursday, May 8, 2025. (AP Photo/JoNel Aleccia) (Jonel Aleccia) People taking Eli Lilly's obesity drug ...

PLAINSBORO, N.J., May 1, 2025 /PRNewswire/ -- Today, Novo Nordisk announced that CVS Caremark, the country's largest Pharmacy Benefit Manager (PBM) has decided that Wegovy® (semaglutide ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 ...